Compare Li Auto Inc (LI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Twist Bioscience Corp — how do they compare? Li Auto Inc trades at $12.25 (market cap $12.43B), while Twist Bioscience Corp trades at $94.97 (market cap $5.45B). The key difference: Li Auto Inc is far larger — about 2.3× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| LI | TWST | |
|---|---|---|
Market Cap | $12.43B | $5.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $30.84 | $102.88 |
52-Week Low | $11.74 | $24.16 |
Enterprise Value | $1.34B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LI Auto trades at $12.42, up 0.24% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31B from $144.5B in 2024. Recent news highlights the launch of new SUV models like the Li L6, aiming to boost deliveries amid competitive pressures.
Outlook remains cautious with analyst consensus at Buy (43.75%) but near-term risks from intense EV competition and profitability challenges. The stock trades below the consensus price target of $14.80, offering potential upside if execution improves, but investors face headwinds from margin pressure and volatile cash flows.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
